Table of Content

Table of Contents

Global Infliximab and Biosimilar Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Infliximab and Biosimilar Market by Value
2.2.1 Global Infliximab and Biosimilar Revenue by Type
2.2.2 Global Infliximab and Biosimilar Market by Value (%)
2.3 Global Infliximab and Biosimilar Market by Production
2.3.1 Global Infliximab and Biosimilar Production by Type
2.3.2 Global Infliximab and Biosimilar Market by Production (%)

3. The Major Driver of Infliximab and Biosimilar Industry
3.1 Historical & Forecast Global Infliximab and Biosimilar Demand
3.2 Largest Application for Infliximab and Biosimilar (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Infliximab and Biosimilar Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Infliximab and Biosimilar Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Infliximab and Biosimilar Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Infliximab and Biosimilar Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Infliximab and Biosimilar Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Infliximab and Biosimilar Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Infliximab and Biosimilar Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Infliximab and Biosimilar Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Infliximab and Biosimilar Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Infliximab and Biosimilar Average Price Trend
12.1 Market Price for Each Type of Infliximab and Biosimilar in US (2018-2022)
12.2 Market Price for Each Type of Infliximab and Biosimilar in Europe (2018-2022)
12.3 Market Price for Each Type of Infliximab and Biosimilar in China (2018-2022)
12.4 Market Price for Each Type of Infliximab and Biosimilar in Japan (2018-2022)
12.5 Market Price for Each Type of Infliximab and Biosimilar in India (2018-2022)
12.6 Market Price for Each Type of Infliximab and Biosimilar in Korea (2018-2022)
12.7 Market Price for Each Type of Infliximab and Biosimilar in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Infliximab and Biosimilar Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Infliximab and Biosimilar

14. Infliximab and Biosimilar Competitive Landscape
14.1 Janssen Biotech
14.1.1 Janssen Biotech Company Profiles
14.1.2 Janssen Biotech Product Introduction
14.1.3 Janssen Biotech Infliximab and Biosimilar Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Merck and Co.
14.2.1 Merck and Co. Company Profiles
14.2.2 Merck and Co. Product Introduction
14.2.3 Merck and Co. Infliximab and Biosimilar Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Pfizer
14.3.1 Pfizer Company Profiles
14.3.2 Pfizer Product Introduction
14.3.3 Pfizer Infliximab and Biosimilar Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Infliximab and Biosimilar Industry (Volume)
Figure 2. Infliximab and Biosimilar Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Infliximab and Biosimilar Revenue in 2022
Figure 5. US Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Infliximab and Biosimilar Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Infliximab and Biosimilar Revenue, by Type (Million USD) (2018-2028)
Table 4. Infliximab and Biosimilar Production, by Type (K Unit) (2018-2028)
Table 5. Infliximab and Biosimilar Demand (K Unit) by Application (2018-2028)
Table 6. Infliximab and Biosimilar Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Infliximab and Biosimilar Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Infliximab and Biosimilar Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Infliximab and Biosimilar in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Janssen Biotech Profiles
Table 61. Janssen Biotech Infliximab and Biosimilar Product Introduction
Table 62. Janssen Biotech Infliximab and Biosimilar Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Janssen Biotech Strategic initiatives
Table 64. Merck and Co. Profiles
Table 65. Merck and Co. Infliximab and Biosimilar Product Introduction
Table 66. Merck and Co. Infliximab and Biosimilar Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Merck and Co. Strategic initiatives
Table 68. Pfizer Profiles
Table 69. Pfizer Infliximab and Biosimilar Product Introduction
Table 70. Pfizer Infliximab and Biosimilar Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Pfizer Strategic initiatives